Biological Activity

Bioactivity / Mechanism

Ezetimibe inhibits cholesterol uptake in human-NPC1L1-expressing cells. In a separate purified-rat-NPC1L1 assay, 20 μM ezetimibe did not appreciably displace bound cholesterol, supporting a distinction between inhibition of uptake and competition for cholesterol binding. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

In Vitro Studies

In NPC1L1-expressing HEK293T cells, 30 µM ezetimibe reduced cholesterol accumulation and limited cholesterol-triggered NPC1L1 internalization. GM3-synthase-deficient cells already had impaired uptake and trafficking, with no notable additional uptake reduction from ezetimibe. These assays used different cholesterol-replenishment conditions. [2]

Cholesterol uptake in control and GM3S-deficient cells

Cell-based study · Human NPC1L1-GFPturbo-expressing HEK293T control and GM3S-knockout cells [2]

Ezetimibe reduced cholesterol accumulation after replenishment in control cells. Uptake was already lower in GM3S-knockout cells, where ezetimibe had no notable additional effect.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
Cellular cholesterol normalized to phospholipids	Relative cholesterol content Reduced by ezetimibe in control cells; no notable additional effect in GM3S-knockout cells.	[2]

Literature-Reported Treatment Conditions

Treatment concentration: 30 µM
Exposure duration: 30-min pretreatment; 60-min cholesterol challenge
Method: After overnight cholesterol depletion, challenge with 30 µg/ml cholesterol–MβCD complex.
Reported limits: Solvent control and sample number for Fig. 1 are not specified in the acquired main text/caption.

Methods and source locations

Compound reported in the paper: Ezetimibe; Compound label in the paper: Ezetimibe (parent compound)

Compound-level evidence; no validation of a specific catalog lot.

Fig. 1 and Results: GM3S deficiency inhibits NPC1L1-dependent cholesterol uptake; Methods: Materials, Measurement of cellular cholesterol, Statistical analysis

Cellular cholesterol normalized to phospholipids: Enzymatic lipid assays; mean ± SD. Untreated and cholesterol-replenished controls were included; plotted comparisons include **P < 0.01 and n.s. No exact bar values extracted. — Fig. 1 and Results: GM3S deficiency inhibits NPC1L1-dependent cholesterol uptake; Methods: Materials, Measurement of cellular cholesterol, Statistical analysis

Cholesterol-triggered NPC1L1 internalization

Cell-based study · NPC1L1-GFPturbo-expressing HEK293T control cells, with GM3S-knockout comparator [2]

Ezetimibe-treated control cells retained more plasma-membrane NPC1L1 signal during cholesterol replenishment than untreated control cells. GM3S-knockout cells also showed impaired internalization.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
Plasma-membrane NPC1L1-GFPturbo fluorescence	Relative intensity Ezetimibe-treated controls and GM3S-knockout cells showed less loss of surface signal than untreated controls.	[2]

Literature-Reported Treatment Conditions

Treatment concentration: 30 µM
Exposure duration: 60-min imaging interval
Method: After overnight depletion, replenish with 60 µg/ml cholesterol, with or without ezetimibe.
Reported limits: A separate ezetimibe pretreatment interval is not stated for imaging. Solvent control and sample number are not specified in the acquired main text/caption.

Methods and source locations

Compound reported in the paper: Ezetimibe; Compound label in the paper: Ezetimibe (parent compound)

Compound-level evidence; no validation of a specific catalog lot.

Fig. 2A–B and associated Results; Methods: Visualization of living cells and fluorescence quantification, Materials, Statistical analysis

Plasma-membrane NPC1L1-GFPturbo fluorescence: Time-lapse confocal imaging; time-zero intensity defined as 100%; mean ± SD. Caption *P < 0.05 refers to control versus GM3S knockout, not a drug-versus-control test. — Fig. 2A–B and associated Results; Methods: Visualization of living cells and fluorescence quantification, Materials, Statistical analysis

Parent-ezetimibe inhibition of cellular cholesterol uptake

Cell-based study · MDCKII cells stably expressing human NPC1L1 [1]

Parent ezetimibe inhibited radiolabeled cholesterol uptake with a reported IC50 of 3.86 μM. This is a cellular uptake endpoint.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
Inhibition of radiolabeled cholesterol uptake	IC50 3.86 μM	[1]

Literature-Reported Treatment Conditions

Treatment concentration: Concentration-response series; IC50 is an assay result
Exposure duration: 1-h compound incubation followed by 90-min cholesterol uptake
Method: 5 nM radiolabeled cholesterol complexed to 10 mM taurocholate; scintillation readout.
Reported limits: Final solvent concentration and parental-cell negative control are not specified for this assay in the acquired main text/caption. No concentration range transcribed from the curve.

Methods and source locations

Compound reported in the paper: Ezetimibe; Compound label in the paper: Ezetimibe (parent compound)

Compound-level evidence; no validation of a specific catalog lot.

Fig. 2D and adjacent Results; Methods: In vitro 3H-cholesterol uptake assay; Statistical analysis

Inhibition of radiolabeled cholesterol uptake: Variable-slope dose-response fit; Fig. 2 legend gives SE error bars, n = 3; replicate type is not specified. — Fig. 2D and adjacent Results; Methods: In vitro 3H-cholesterol uptake assay; Statistical analysis

Cholesterol binding in the presence of ezetimibe

Biochemical assay · Purified full-length rat NPC1L1 protein [1]

Ezetimibe did not appreciably reduce bound radiolabeled cholesterol under these conditions, whereas unlabeled cholesterol and the tested phytosterols competed for binding.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
NPC1L1-bound radiolabeled cholesterol	Relative binding Similar cholesterol binding with ezetimibe and without competitor; reduced with unlabeled cholesterol, β-sitosterol or stigmasterol.	[1]

Literature-Reported Treatment Conditions

Treatment concentration: 20 μM ezetimibe; 0.5 μM labeled cholesterol; 0.62 μM NPC1L1
Exposure duration: Overnight at 23°C
Method: Protein-bound tracer isolated by size-exclusion chromatography and quantified by scintillation.
Vehicle: Ezetimibe-series compounds added in DMSO; final percentage not specified.
Reported limits: Control solvent composition is not explicitly specified in the binding caption.

Methods and source locations

Compound reported in the paper: Ezetimibe; Compound label in the paper: Ezetimibe (parent compound)

Compound-level evidence; no validation of a specific catalog lot.

Fig. 4D and Results: Ezetimibe blocks a tunnel connecting NTD to SSD; Methods: Protein expression and purification, Cholesterol binding assay, Statistical analysis

NPC1L1-bound radiolabeled cholesterol: Competitors tested at 20 μM; normalized to control. SE error bars, n = 4; no exact bar heights inferred. — Fig. 4D and Results: Ezetimibe blocks a tunnel connecting NTD to SSD; Methods: Protein expression and purification, Cholesterol binding assay, Statistical analysis

In Vivo Studies

In mice expressing human NPC1L1 only in liver, ezetimibe at 10 mg/kg daily by oral gavage for four days increased biliary cholesterol molar percentage 8.5-fold versus vehicle. Under this regimen, fecal neutral sterol excretion did not increase and plasma cholesterol did not normalize to NPC1L1-knockout control levels. [3]

Short-course treatment in liver-only NPC1L1 mice

Animal study · Male L1LivOnly mice expressing human NPC1L1 only in liver on an endogenous-NPC1L1-knockout background, compared with L1-KO mice [3]

Four days of ezetimibe increased biliary cholesterol molar percentage in L1LivOnly mice. Fecal neutral sterol excretion was unchanged, and plasma total cholesterol did not normalize to L1-KO levels.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
Gallbladder biliary cholesterol molar percentage	Fold change 8.5-fold increase versus vehicle-treated L1LivOnly mice	[3]
Fecal neutral sterol excretion	Treatment response No increase under the tested conditions	[3]
Plasma total cholesterol	Normalization to knockout controls Not normalized to L1-KO levels after 4 days	[3]

Conditions shared by the study groups

Route: Oral gavage
Frequency: Daily on days 18–21
Treatment course: 4 days; diet continued through the treatment period
Vehicle: 100 µl of 0.4% methyl cellulose

Study groups and reported outcomes
Group / dose	Comparator	Observed result	Reference
L1-KO + vehicle 100 µl of 0.4% methyl cellulose	Matched vehicle-treated genotype; L1-KO provides the no-NPC1L1 genetic comparator.	Knockout reference for biliary, fecal and plasma endpoints.	[3]
L1-KO + ezetimibe 10 mg/kg body weight	Matched vehicle-treated genotype; L1-KO provides the no-NPC1L1 genetic comparator.	Knockout drug comparator; plasma cholesterol remained lower than in liver-only transgenic groups.	[3]
L1LivOnly + vehicle 100 µl of 0.4% methyl cellulose	Matched vehicle-treated genotype; L1-KO provides the no-NPC1L1 genetic comparator.	Low biliary cholesterol molar percentage; elevated plasma total cholesterol versus vehicle-treated L1-KO.	[3]
L1LivOnly + ezetimibe 10 mg/kg body weight	Matched vehicle-treated genotype; L1-KO provides the no-NPC1L1 genetic comparator.	Biliary cholesterol molar percentage increased 8.5-fold versus liver-only vehicle; fecal neutral sterol output did not increase and plasma cholesterol was not normalized.	[3]

L1-KO + vehicle: Model: Male L1-KO mice; ~2 months old at diet initiation; 0.2% cholesterol diet; Reported limits: Drug supplier, catalog/lot and separate analytical identity confirmation are not reported in the acquired manuscript.

L1-KO + ezetimibe: Model: Male L1-KO mice; ~2 months old at diet initiation; 0.2% cholesterol diet; Reported limits: Drug supplier, catalog/lot and separate analytical identity confirmation are not reported in the acquired manuscript.

L1LivOnly + vehicle: Model: Male L1LivOnly mice; ~2 months old at diet initiation; 0.2% cholesterol diet; Reported limits: Drug supplier, catalog/lot and separate analytical identity confirmation are not reported in the acquired manuscript.

L1LivOnly + ezetimibe: Model: Male L1LivOnly mice; ~2 months old at diet initiation; 0.2% cholesterol diet; Reported limits: Drug supplier, catalog/lot and separate analytical identity confirmation are not reported in the acquired manuscript.

Methods and source locations

Compound reported in the paper: Ezetimibe; Compound label in the paper: Ezetimibe (parent compound)

Compound-level evidence; no validation of a specific catalog lot.

Fig. 3A–C; Results 3.5; Methods 2.1–2.5; Fig. 1A model validation

Gallbladder biliary cholesterol molar percentage: Reported fold change in Results 3.5; Fig. 3 mean ± SEM, 5–6 samples; ANOVA with Tukey-Kramer comparison, P < 0.05 for indicated differences. — Fig. 3A; Results 3.5

Fecal neutral sterol excretion: Reported in Results 3.5 and Fig. 3B; same four-arm experiment. — Fig. 3B; Results 3.5

Plasma total cholesterol: Fig. 3C and Results 3.5; this does not establish a significant increase caused by ezetimibe. — Fig. 3C; Results 3.5 and Discussion

L1-KO + vehicle · Fig. 3A–C; Results 3.5; Methods 2.1–2.5; Fig. 1A model validation

L1-KO + ezetimibe · Fig. 3A–C; Results 3.5; Methods 2.1–2.5; Fig. 1A model validation

L1LivOnly + vehicle · Fig. 3A–C; Results 3.5; Methods 2.1–2.5; Fig. 1A model validation

L1LivOnly + ezetimibe · Fig. 3A–C; Results 3.5; Methods 2.1–2.5; Fig. 1A model validation

Specifications

Manufacturer	Adooq Bioscience
CAS Number	163222-33-1
Formula	C₂₄H₂₁F₂NO₃
Molecular Weight	409.4
Synonyms	Zetia; Ezetrol
SMILES	C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

Solvent	Reported Solubility
DMSO	75 mg/mL (183.19 mM)
Water	Insoluble
Ethanol	75 mg/mL (183.19 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration: 9 mg/mL
Vehicle: 2% DMSO+30% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

[1] Huang CS, Yu X, Fordstrom P, et al. Cryo-EM structures of NPC1L1 reveal mechanisms of cholesterol transport and ezetimibe inhibition. Science advances (2020). PMID: 32596471 DOI: 10.1126/sciadv.abb1989 Source material
[2] Nihei W, Nagafuku M, Hayamizu H, et al. NPC1L1-dependent intestinal cholesterol absorption requires ganglioside GM3 in membrane microdomains. Journal of lipid research (2018). PMID: 30242108 DOI: 10.1194/jlr.m089201 Source material
[3] Tang W, Jia L, Ma Y, et al. Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-Like 1 only in liver. Biochimica et biophysica acta (2011). PMID: 21683156 DOI: 10.1016/j.bbalip.2011.05.013 Source material

Publications

2 publications citing this product

Yuki Ishii, .et al. , J Cell Sci, 2025, Apr 1;138(7):jcs263487 PMID: 40065746
Nihei W, .et al. , J Lipid Res, 2018, Nov; 59(11): 2181-2187 PMID: 30242108

Documents & Downloads

Ezetimibe

Publications for Ezetimibe

Select a Size

Package Sizes

DMSO Solution

Ezetimibe 5 mg

Free Aliquoting for Your Order

Biological Activity

Bioactivity / Mechanism

In Vitro Studies

Cholesterol uptake in control and GM3S-deficient cells

Literature-Reported Treatment Conditions

Cholesterol-triggered NPC1L1 internalization

Literature-Reported Treatment Conditions

Parent-ezetimibe inhibition of cellular cholesterol uptake

Literature-Reported Treatment Conditions

Cholesterol binding in the presence of ezetimibe

Literature-Reported Treatment Conditions

In Vivo Studies

Short-course treatment in liver-only NPC1L1 mice

Conditions shared by the study groups

Specifications

Storage & Solubility

In Vitro Solubility

Reported Solubility

Preparing Stock Solutions

In Vivo Preparation

Storage

Research References

Publications

Added to your cart